Literature DB >> 7975247

Age-related development of human memory T-helper and B-cell responses toward parainfluenza virus type-1.

F S Smith1, A Portner, R J Leggiadro, E V Turner, J L Hurwitz.   

Abstract

Human parainfluenza-1 virus (hPIV-1) infections are a major cause of respiratory illness in young children. While children and adults are each susceptible to hPIV-1 infection, the clinical symptoms in adults are mild and hospitalizations are rare. One explanation for the differences in disease severity is that immune memory responses are simply inferior in children as compared to adults and cannot counter virus growth. Alternatively, it has been suggested that immune (particularly T-helper (TH) cell) responses toward respiratory viruses are superior in children versus older individuals, and that these responses contribute to, rather than protect from, disease symptoms. As a test of these possibilities, we analyzed hPIV-1-specific T-helper (TH) and B-cell memory responses among individuals of various ages, including children hospitalized with hPIV-1-induced croup. Experiments revealed: (1) hPIV-1-specific B-cell and class-II restricted TH-cell proliferative responses were present in all tested adults. (2) TH-cells responded to internal viral proteins as well as to the external glycoprotein, hemagglutinin-neuraminidase. (3) Immune responses were highly cross-reactive with Sendai virus. (4) Memory B-cell and TH-cell responses were extremely poor in young children, inclusive of children tested upon hospital entry for hPIV-1-induced croup. In total, results did not support the theory that naturally induced hPIV-specific memory responses cause respiratory illness. Rather, results showed a correlation between memory and a good clinical outcome and highlighted Sendai virus as a strong candidate for an hPIV-1 vaccine.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7975247     DOI: 10.1006/viro.1994.1665

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  16 in total

1.  A case of adult croup.

Authors:  Stephen R Beckwith
Journal:  Intern Emerg Med       Date:  2008-03-04       Impact factor: 3.397

2.  Robust IgA and IgG-producing antibody forming cells in the diffuse-NALT and lungs of Sendai virus-vaccinated cotton rats associate with rapid protection against human parainfluenza virus-type 1.

Authors:  R Sealy; B G Jones; S L Surman; J L Hurwitz
Journal:  Vaccine       Date:  2010-08-01       Impact factor: 3.641

3.  Inter- and intra-patient sequence diversity among parainfluenza virus-type 1 nucleoprotein genes.

Authors:  V P Dave; S V Hetherington; A Portner; R J Leggiadro; J L Hurwitz
Journal:  Virus Genes       Date:  1997       Impact factor: 2.332

Review 4.  Vaccines for the Paramyxoviruses and Pneumoviruses: Successes, Candidates, and Hurdles.

Authors:  Charles J Russell; Eric A F Simões; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2018-01-11       Impact factor: 2.257

5.  Phenotypes and functions of persistent Sendai virus-induced antibody forming cells and CD8+ T cells in diffuse nasal-associated lymphoid tissue typify lymphocyte responses of the gut.

Authors:  Rajeev Rudraraju; Sherri Surman; Bart Jones; Robert Sealy; David L Woodland; Julia L Hurwitz
Journal:  Virology       Date:  2011-01-11       Impact factor: 3.616

6.  Residues in the heptad repeat a region of the fusion protein modulate the virulence of Sendai virus in mice.

Authors:  Laura E Luque; Olga A Bridges; John N Mason; Kelli L Boyd; Allen Portner; Charles J Russell
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

7.  Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV.

Authors:  Bart Jones; Xiaoyan Zhan; Vasiliy Mishin; Karen S Slobod; Sherri Surman; Charles J Russell; Allen Portner; Julia L Hurwitz
Journal:  Vaccine       Date:  2009-02-04       Impact factor: 3.641

Review 8.  Mouse models for the study of mucosal vaccination against otitis media.

Authors:  Albert Sabirov; Dennis W Metzger
Journal:  Vaccine       Date:  2008-02-04       Impact factor: 3.641

9.  Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV.

Authors:  Toru Takimoto; Julia L Hurwitz; Chris Coleclough; Cecilia Prouser; Sateesh Krishnamurthy; Xiaoyan Zhan; Kelli Boyd; Ruth A Scroggs; Brita Brown; Yoshiyuki Nagai; Allen Portner; Karen S Slobod
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

10.  Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections.

Authors:  Xiaoyan Zhan; Karen S Slobod; Sateesh Krishnamurthy; Laura E Luque; Toru Takimoto; Bart Jones; Sherri Surman; Charles J Russell; Allen Portner; Julia L Hurwitz
Journal:  Vaccine       Date:  2008-05-01       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.